Published in Blood Weekly, April 3rd, 2003
Enric Carreras and colleagues at the University of Barcelona Hospital Clinic conducted a "phase II trial to evaluate the feasibility and toxicity of CD34+ selected" autologous stem cell transplantation (CD34+/ASCT).
Treatment with CD34+/ASCT slowed or reversed MS progression with limited toxicity, Carreras and coauthors found.
The researchers performed CD34+/ASCT on 15 patients with advanced secondary progressive (SP) or relapsing-remitting (RR) MS. All of the transplanted...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.